Insulet Target Price

Analysts' average 12-month price target for Insulet is $170.

Get informed when a big investor buys or sells

+ Follow

Share Price

$152.48

Average Target Price

$168.75

10.7% upside

12 analysts in the last 4 months

High: $200 | Low: $144

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-11-04	JefferiesMatthew Taylor	$200	31.2% upside
2026-10-12	JefferiesMatthew Taylor	$190	24.6% upside
2026-10-06	Barclays	$150	1.6% downside
2026-08-06	Robert W. BairdJeff Johnson	$175	14.8% upside
2026-08-06	Bernstein	$175	14.8% upside
2026-08-06	Leerink PartnersMike Kratky	$145	4.9% downside
2026-08-06	RBC Capital	$160	4.9% upside
2026-08-06	Raymond JamesJayson Bedford	$180	18% upside
2026-08-06	Canaccord GenuityWilliam Plovanic	$179	17.4% upside
2026-08-05	Wells FargoLarry Biegelsen	$144	5.6% downside
2026-08-05	Truist Financial	$153	0.3% upside
2026-07-28	UBS	$174	14.1% upside
2026-07-13	Truist Financial	$210	37.7% upside
2026-07-13	RBC Capital	$245	60.7% upside
2026-07-10	Stifel Nicolaus	$225	47.6% upside
2026-07-06	Evercore ISI	$180	18% upside
2026-06-23	Deutsche Bank	$190	24.6% upside
2026-06-11	UBS	$219	43.6% upside
2026-06-11	Truist FinancialRichard Newitter	$219	43.6% upside
2026-06-08	Raymond James	$216	41.7% upside
2026-05-27	Goldman SachsDavid Roman	$205	34.4% upside
2026-05-26	BTIG	$235	54.1% upside
2026-05-07	Goldman Sachs	$237	55.4% upside
2026-05-07	RBC CapitalShagun Singh	$280	83.6% upside
2026-05-07	Truist FinancialRichard Newitter	$250	64% upside
2026-05-07	Evercore ISI	$200	31.2% upside
2026-05-07	Oppenheimer	$210	37.7% upside
2026-05-07	Stifel Nicolaus	$250	64% upside
2026-05-07	Canaccord GenuityWilliam Plovanic	$249	63.3% upside
2026-05-07	Bernstein	$200	31.2% upside
2026-05-07	BarclaysMatt Miksic	$198	29.9% upside
2026-05-06	BTIG	$260	70.5% upside
2026-04-24	Redburn Partners	$220	44.3% upside
2026-04-15	Truist FinancialRichard Newitter	$315	106.6% upside
2026-04-14	RBC CapitalShagun Singh	$325	113.1% upside
2026-02-19	Truist Financial	$360	136.1% upside
2026-02-19	Evercore ISI	$340	123% upside
2026-02-19	Goldman SachsDavid Roman	$326	113.8% upside
2026-02-19	Oppenheimer	$300	96.7% upside
2026-02-19	Bernstein	$330	116.4% upside
2026-02-19	Barclays	$286	87.6% upside
2026-02-18	Canaccord GenuityWilliam Plovanic	$435	185.3% upside
2026-02-04	Stifel Nicolaus	$350	129.5% upside
2026-01-12	Barclays	$274	79.7% upside
2026-01-09	BernsteinLee Hambright	$380	149.2% upside
2026-01-09	Goldman SachsDavid Roman	$365	139.4% upside
2025-12-18	Truist Financial	$390	155.8% upside
2025-12-17	Canaccord Genuity	$450	195.1% upside
2025-12-16	Evercore ISI	$370	142.7% upside
2025-11-24	Canaccord Genuity	$432	183.3% upside

Insulet (PODD) FAQ

Insulet (PODD) currently reports a target price of $170. Use the charts on this page to explore Insulet's target price history and peer comparisons.

Analysts' average 12-month price target for Insulet is $170, about 10.7% upside from the current share price of $152.48. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $170, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Insulet, and consider following PODD for alerts when major investors trade the stock.

Insulet is classified in the Healthcare sector. On target price, it currently shows $170. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PODD with unrelated industries.